DGAP-News: Vita 34 AG

NOT FOR DISTRIBUTION, PUBLICATION OR DISCLOSURE IN OR WITHIN THE US, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL. PLEASE NOTE THE IMPORTANT NOTICE AT THE END OF THIS COMMUNICATION.

Vita 34 completes rights issue - multiple times oversubscribed

Leipzig, Germany, July 28, 2017 - The Management Board of Vita 34 AG, Leipzig (ISIN: DE000A0BL849, SIN: A0BL84) (the "Company") today decided - with the Supervisory Board's approval - to set the final scope of the rights issue to be executed to a total of 816,810 new shares. The vast majority of Vita 34 shareholders had exercised their subscription rights when the subscription period ended on July 27, 2017. The remaining shares were placed with qualified investors. The price per share was EUR 6.10. The rights issue was oversubscribed multiple times.

"The strong demand from our shareholders and from investors reflects the capital market's highly positive attitude towards our strategy," comments Dr. Wolfgang Kirsch, Chairman of the Management Board of Vita 34 AG. "As planned, we will use the issue proceeds of almost EUR 5 million from this capital increase to complete the acquisition of Seracell Pharma AG. The integration of Seracell is proceeding on schedule, and we expect it to be nearly completed by the end of the year. We thank all of our shareholders for their trust."

The rights issue will increase the Company's share capital by EUR 816,810.00 from its current level of EUR 3,329,149.00 to EUR 4,145,959.00 in return for cash contributions by issuing 816,810 new no-par value registered shares, each with a notional par value of EUR 1.00 and carrying dividend rights from January 1, 2017.

The New Shares are to be admitted to trading on the regulated market (Prime Standard) on the Frankfurt Stock Exchange without the publication of a securities prospectus. The New Shares are expected to be included into the existing listing on the Frankfurt stock exchange on August 08, 2017.

IMPORTANT NOTICE:

This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities.

This publication may not be released, published or distributed in the United States of America, Australia, Japan or Canada. This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities in Vita 34 AG (the "Shares") within the United States of America, Germany or any other state. The Shares may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares are not and will not be registered in accordance with the provisions of the U.S. Securities Act.

As far as this document contains forward-looking statements these statements do not constitute facts and may be identified by words such as "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Vita 34 AG and persons acting in conjunction with Vita 34 AG. Any forward-looking statements contained in this document are based on current plans, estimates and projections which Vita 34 AG and persons acting in conjunction with Vita 34 AG have made to the best of their knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Vita 34 AG or persons acting in conjunction with Vita 34 AG. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.

Company profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Some 160,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.

Related news

July 10, 2017 Vita 34 AG resolves to implement rights issue against cash contributions by using its Authorized Capital